Announcement on Obtaining Drug Registration Certificate by Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Obtaining Drug Registration Certificate by Subsidiary
Filed with SSE ·
6ix hasn’t read this filing yet.
Zhejiang Huahai Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Huahai Pharmaceutical
- Announcement on Progress in Legal Proceedings Involving the Company and Its Subsidiaries
- Announcement on Obtaining the Notice on Approval of Drug Supplement Application
- Announcement on Expected Decrease in Performance for 2025
- On-Site Inspection Report of Zheshang Securities Co., Ltd. on Continuous Supervision over ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. in 2025
- Announcement on Release of Pledge of Partial Equity of Shareholder
Later from Zhejiang Huahai Pharmaceutical
- Announcement on Obtaining the U.S. FDA Approval for the Product Gabapentin Capsules
- Announcement on Subsidiary HB0025 Injection Initiating Endometrial Cancer Phase III Clinical Trial
- Announcement on Maturity of Partial Idle Raised Funds Used for Cash Management
- Announcement on Resolutions of the 8th Extraordinary Meeting of the 9th Board of Directors
- Announcement on Resolutions of the 9th Extraordinary Meeting of the 9th Board of Directors
Follow Zhejiang Huahai Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Huahai Pharmaceutical